Despite the recent sell-off in resources and materials stocks that we have witnessed over the past few weeks, investors with a penchant for miners, explorers and energy companies would be feeling pretty chuffed (comparatively, that is - let's observe a moment of silence for growth investors). Potash prices, for example,.
BHP chief executive Mike Henry bets the company on two global mega-trends afr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afr.com Daily Mail and Mail on Sunday newspapers.
A dark cloud hangs over the energy sector as it faces a climate change reckoning. But some are convinced there is money to be made as the world recovers from COVID-19.
Georgia Senate race rattles markets, energy rallies
Share
Global markets sold-off on Wednesday as investors rushed to price in the prospect of Democrats taking full control of Congress in the US, with the party set to win a majority in the Senate.
While the result had not been declared at the market close on Wednesday, multiple news outlets were predicting the Democrats would pick up both seats in Georgia’s Senate run-off election, sending the local sharemarket and US futures tumbling.
Milford s William Curtayne.
Louise Kennerley
The S&P/ASX 200 Index plunged 74.8 points, or 1.1 per cent, to 6607.1, with energy the only sector spared from the sell-down after OPEC and its allies agreed to cut production further, surprising expectations.
With the ASX tipped to outperform in 2021, shares in this sector could rocket
Bernd Struben | December 23, 2020 4:00pm |
More on: Image source: Getty Images
Global share markets are entering the final days of 2020 in a tug of war between the same 2 prevailing forces that have dominated share prices since February.
COVID-19, now responsible for more than 1.7 million deaths around the globe, continues to roil investors.
Shares largely surged on the back of multiple successful vaccine approvals in recent weeks. But the new, more transmissible variant of the virus coming out of the United Kingdom is raising fresh uncertainties.
Manufacturers are broadly expressing confidence that their vaccines should prove effective against the new mutation. But it will be several weeks before clinical trials can confirm that.